

# Cerebellar degeneration and cerebellar-cortical interactions associated with placebo-nocebo effects: a pilot study

Antonia Baumgarten<sup>1</sup>, Eline S. Kruithof<sup>1</sup>, Enzo Nio<sup>1</sup>, Frederik Schlitt-Nguyen<sup>1</sup>, Marie Arend<sup>1</sup>, Andreas Thieme<sup>1</sup>, Milan Rieger<sup>1</sup>, Thomas M. Ernst<sup>1</sup>, Helena Hartmann<sup>1</sup>, Ulrike Bingel<sup>1</sup>, Michael Rose<sup>2</sup>, & Dagmar Timmann<sup>1</sup>


<sup>1</sup>Dept. of Neurol. and C-TNBS, Essen Univ. Hospital, Univ. of Duisburg-Essen, Essen, Germany,

<sup>2</sup>Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf


1

## Introduction

The contribution of the cerebellum to placebo and nocebo effects has rarely been studied. The aim of the present study is to show that placebo and nocebo effects are reduced in patients with cerebellar disease and that the cerebellum contributes to treatment expectations via its connections with cortical areas including the DLPFC. Interactions will be tested using EEG recording and structural MRI.



**Reduced placebo and preserved nocebo effects in patients with cerebellar degeneration**  
Patients n = 27; Controls n = 27.  
Schlitt-Nguyen et al., in preparation.



**Top down pain modulatory network** (DLPFC, ACC, Thalamus and PAG) [modified from Enck et al. 2013].


**Pilot study aims:**

- Test placebo-nocebo paradigm adapted for EEG in young and healthy participants.
- Initial testing of patients with cerebellar degeneration.


2

## Methods

### Paradigm used in previous studies



### Experimental Setup




### Implementation of EEG

- Short time intervals (e.g. heat stimulation)
- High number of trials
- Movement control trials
- Expectation ratings in each trial

### Pilot (healthy) Participants

| Group  | N  | Mean Age | SD Age |
|--------|----|----------|--------|
| Total  | 20 | 25.55    | 4.21   |
| Male   | 10 | 27.20    | 4.54   |
| female | 10 | 23.90    | 3.28   |


### Experimental Task



\* Expectation ratings only in test phase

3

## Behavioral findings



## EEG findings

↑power of theta, alpha and beta in the **placebo > control** condition during heat pain stimulation.


p = 0.0060  
Frequency range: 4.03 - 19.04 Hz  
Time range: 0.100 - 0.950 s

↑power of theta, alpha and beta in the **nocebo > control** condition during heat pain anticipation, stimulation.

1 p = 0.0500  
Frequency range: 4.03 - 22.58 Hz  
Time range: -2.350 - -1.700 s  
2 p = 0.0060  
Frequency range: 4.03 - 15.99 Hz  
Time range: -0.750 - 0.850 s

↑power of theta, alpha and beta in the **placebo** as well as **nocebo > control** condition during heat pain anticipation and stimulation.

p = 0.0060  
Frequency range: 4.03 - 19.04 Hz  
Time range: -0.750 - 1.000 s



4


## Conclusions

- The placebo nocebo paradigm adapted for EEG induced significant placebo and nocebo effects, and can be applied in cerebellar patients.
- Placebo and nocebo expectations modulated oscillatory activity during heat pain processing, reflected by increased theta, alpha, and beta power compared to the control condition. Nocebo effects emerged already during pain anticipation, whereas placebo-related increases were mainly observed during heat pain stimulation.

5

## Study Cohort

## Study Design



**Hypotheses for patient study:**

1. Patients show a reduction in brain oscillations during the anticipation and experience of pain.
2. Reduced placebo and nocebo effects in patients are related to reduced connectivity between the cerebellum and the DLPFC.

40 Patients with cerebellar degeneration  
– SCA2/7B  
– SCA6

40 Controls  
– healthy  
– Age matched  
– Sex matched



**3 T-MRI Scan**  
– MP2RAGE  
– Resting State  
– DWI  
– QSM

**Neurological examination**  
– SARA and CCAS scales  
– QST

**Placebo/ nocebo paradigm**

## Patient Study

### Preliminary Data



**Abbreviations**  
EOG = Electrooculography; EMG = Electromyography; VAS = visual analog scale; ITI = inter-trial interval; SD = standard deviation; SCA = spinocerebellar ataxia; DWI = diffusion-weighted imaging; QSM = Quantitative Susceptibility Mapping; QST = quantitative sensory testing

**References**  
Ruscheweyh R, Kühnel M, Filippopoulos F, Blum B, Eggert T, Straube A. Altered experimental pain perception after cerebellar infarction. Pain. 2014 Jul;155(7):1303-1312. doi: 10.1016/j.pain.2014.04.006.  
Schlitt-Nguyen et al. in preparation  
Kunkel A, Schmidt K, Hartmann H, Strietzel J, Sperzel JL, Wiech K, Bingel U. Nocebo effects are stronger and more persistent than placebo effects in healthy individuals. Elife. 2025 Oct 28;14:RP105753. doi: 10.7554/eLife.105753.  
Colloca L, Petrovic P, Wager TD, Ingvar M, Benedetti F. How the number of learning trials affects placebo and nocebo responses. Pain 2010 Nov; 151(2):p 430-439. doi: 10.1016/j.pain.2010.08.007  
Wittkamp CA, Wolf M, Rose, M. The neural dynamics of positive and negative expectations of pain. eLife 2024 13:RP97793. doi: 10.7554/eLife.97793.3